Takakura Akira, Kurita Akinobu, Asahara Takashi, Yokoba Masanori, Yamamoto Michiko, Ryuge Shinichiro, Igawa Satoshi, Yasuzawa Yukitoshi, Sasaki Jiichiro, Kobayashi Hirosuke, Masuda Noriyuki
Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374.
Oncol Lett. 2012 Mar;3(3):520-524. doi: 10.3892/ol.2011.519. Epub 2011 Dec 9.
One of the dose-limiting toxicities of irinotecan hydrochloride (CPT-11) is delayed-onset diarrhea. CPT-11 is converted to its active metabolite, SN-38, which is conjugated to SN-38 glucuronide (SN-38G). SN-38G excreted in the intestinal lumen is extensively deconjugated by bacterial β-glucuronidase, resulting in the regeneration of SN-38, which causes diarrhea. However, the deconjugation of SN-38G by the intestinal microflora remains to be clarified. This study aimed to investigate the microbial transformation of SN-38G by an anaerobic mixed culture of rat cecal microorganisms. Concentrations of SN-38G and SN-38 were then determined using high-performance liquid chromatography. Complete deconjugation of SN-38G to SN-38 in the mixed cultures was observed within 1 h of incubation, with 62.7% of the added SN-38G being found in the supernatant. Approximately 80.4% of the SN-38 in the supernatant was bound to protein, and the remaining 19.6% was detected as active free SN-38. In total, only 12.3% (19.6 × 62.7%) of the SN-38G added to the test tube was found in the supernatant in the ultrafiltrable free form, indicating that approximately 90% of the SN-38G added to the growth medium either remained adsorbed onto the pelleted fraction or occurred in a protein-bound form in the supernatant. The remaining 10% of the SN-38G added to the growth medium existed in the unbound form, the form capable of causing damage to the intestinal membrane. In conclusion, these results indicated that the greater part of the SN-38 produced from SN-38G by the action of bacterial β-glucuronidase is rapidly adsorbed onto intestinal bacterial cell walls or dietary fibers in pelleted fraction, and only 10% remains in the ultrafiltrable unbound form in the intestinal luminal fluid.
盐酸伊立替康(CPT-11)的剂量限制性毒性之一是迟发性腹泻。CPT-11转化为其活性代谢产物SN-38,后者与SN-38葡糖醛酸苷(SN-38G)结合。排泄到肠腔中的SN-38G被细菌β-葡糖醛酸酶广泛地去结合,导致SN-38再生,进而引起腹泻。然而,肠道微生物群对SN-38G的去结合作用仍有待阐明。本研究旨在通过大鼠盲肠微生物的厌氧混合培养来研究SN-38G的微生物转化。然后使用高效液相色谱法测定SN-38G和SN-38的浓度。在混合培养物中,孵育1小时内观察到SN-38G完全去结合为SN-38,在上清液中发现62.7%的添加SN-38G。上清液中约80.4%的SN-38与蛋白质结合,其余19.6%被检测为活性游离SN-38。总体而言,添加到试管中的SN-38G仅有12.3%(19.6×62.7%)以可超滤的游离形式存在于上清液中,这表明添加到生长培养基中的SN-38G约90%要么仍吸附在沉淀部分,要么以上清液中蛋白质结合的形式存在。添加到生长培养基中的其余10%的SN-38G以未结合形式存在,这种形式能够对肠膜造成损伤。总之,这些结果表明,由细菌β-葡糖醛酸酶作用从SN-38G产生的SN-38的大部分迅速吸附到肠道细菌细胞壁或沉淀部分的膳食纤维上,只有10%以可超滤的未结合形式保留在肠腔液中。